ArticleJournal of neurovirology2013
The Alzheimer's disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected persons.
Article in Journal of neurovirology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Montreal Cognitive Assessment (MoCA) for HIV-Associated Neurocognitive Disorders.Neuropsychology review · 2019Pooled it
- AD-8 for detection of dementia across a variety of healthcare settings.The Cochrane database of systematic reviews · 2019Pooled it
- Machine-Learning Approach to Identify Tissue Inhibitors of Metalloproteinases (TIMP) and Clinical Variables Predicting Executive Phenotypes in HIV-infected Adults.Open forum infectious diseases · 2026Article
- Mutational effects of the asparagine198 and glutamate223 residues on the human norepinephrine transporter on basal and HIV-1 Tat protein-induced inhibition of dopamine transport.European journal of pharmacology · 2025Article
- Impact of HIV-1 tat protein on methamphetamine-induced inhibition of vesicular monoamine transporter2-mediated dopamine transport and methamphetamine conditioned place preference in HIV-1 tat transgenic mice.European journal of pharmacology · 2024Article
- Accelerated neurodegeneration of basal forebrain cholinergic neurons in HIV-1 gp120 transgenic mice: Critical role of the p75 neurotrophin receptor.Brain, behavior, and immunity · 2024Article
- An Automated Virtual Reality Program Accurately Diagnoses HIV-Associated Neurocognitive Disorders in Older People With HIV.Open forum infectious diseases · 2023Article
- Telephone-based evaluation of cognitive impairment and mood disorders in cardiac arrest survivors with good neurologic outcomes: a retrospective cohort study.Scientific reports · 2023Article
- Postsurgery Subjective Cognitive and Short-Term Memory Impairment Among Middle-Aged Chinese Patients.JAMA network open · 2023Article
- Primary Care of the Person Living with HIV.Pathogens (Basel, Switzerland) · 2022Review
- International HIV Dementia Scale for HIV-Associated Neurocognitive Disorders: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2021Review
- Central Auditory Tests to Track Cognitive Function in People With HIV: Longitudinal Cohort Study.JMIR formative research · 2021Article
- Screening for HIV-Associated Neurocognitive Disorders: Sensitivity and Specificity.Current topics in behavioral neurosciences · 2021Review
- Development of a neurocognitive test battery for HIV-associated neurocognitive disorder (HAND) screening: suggested solutions for resource-limited clinical settings.AIDS research and therapy · 2019Article
- Cerebral Vasoreactivity Evaluated by the Breath-Holding Challenge Correlates With Performance on a Cognitive Screening Test in Persons Living With Treated HIV Infection in China.Journal of acquired immune deficiency syndromes (1999) · 2018Article
- The association between asymptomatic and mild neurocognitive impairment and adherence to antiretroviral therapy among people living with human immunodeficiency virus.Southern African journal of HIV medicine · 2018Article
- Screening for neurocognitive impairment in HIV-positive adults aged 50 years and older: Montreal Cognitive Assessment relates to self-reported and clinician-rated everyday functioning.Journal of clinical and experimental neuropsychology · 2017Article
- HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment.Journal of neurology · 2017Review
- Temporal processsing demands in the HIV-1 transgenic rat: Amodal gating and implications for diagnostics.International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience · 2017Article
- Topographies of Cortical and Subcortical Volume Loss in HIV and Aging in the cART Era.Journal of acquired immune deficiency syndromes (1999) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
The diagnosis of human immunodeficiency virus (HIV)-associated neurocognitive impairment is time-intensive and often omitted in busy outpatient settings. Brief screening tools are needed. The Montreal Cognitive Assessment (MoCA) and the Alzheimer's disease (AD)-8 have been used in neurodegenerative disorders. We evaluated the sensitivity and specificity of these brief screening tools in HIV-infected persons. The AD-8, MoCA, and formal neuropsychological testing were administered to 200 HIV-infected patients who were followed at a single institution. Normalized scores on formal neuropsychological testing were used to define neurocognitive impairment. The sensitivity and specificity of the MoCA and AD-8 were assessed to diagnose the impairment. Neurocognitive impairment was highly prevalent in this cohort: 127 persons (64 %) were diagnosed with neurocognitive impairment based on formal testing. Using the AD-8 and MoCA, 113 (57 %) and 101 (51 %) persons were identified with neurocognitive impairment, respectively. The sensitivity and specificity of MoCA were 63 % and 71 %, respectively. The sensitivity and specificity of AD-8 were 61 % and 51 %, respectively. Our findings highlight that brief screening tools correlate with formal neuropsychological testing. However, the sensitivities of these screening tools are lower than desired. Nevertheless, given their ease in administration, these tools could assist as a first line for identifying individuals who may subsequently require formal neuropsychological testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.